Interactions of taurine and beta-alanine with central nervous system neurotransmitter receptors

Varying amounts of labeled phenylethylamine (PEA), ptyramine (TRM) and phenylacetic acid (PAAc) were recovered from rabbit brain homogenates at different intervals after the intraventricular (ivn) administration of either labeled L-phenylalanine or PEA. Previous administration of imipramine or amphetamine decreased the recoveries of PEA and PAAc. Imipramine increased the recovery of TRM, which was not affected by amphetamine. The ivn injection of TRM, 2, 5, 10 and 20 min before sacrifice resulted in the recoveries of decreasing amounts of PEA. Pretreatment of the animals with chlorpromazine, haloperidol or smaller doses of Δ⁹-tetrahydrocannabinol (Δ⁹-THC) did not affect PEA recoveries from brain homogenates, whereas amphetamine or larger Δ⁹-THC doses resulted in increased and decreased PEA yields, respectively.These studies further show the existence of an $\text{in}$$\text{vivo}$ brain metabolic pathway linking L-phenylalanine to PEA and TRM. It also shows that these pathways are modified by a number of centrally active drugs.     

Interactions between cannabidiol and delta9-THC during abstinence in morphine-dependent rats.

Male rats, each implanted with a pellet containing 75 mg morphine, were administered naloxone 72 hours later to precipitate abstinence. Two hours before naloxone, animals were pretreated acutely with either 10 mg/kg cannabidiol (CBD) or the vehicle. One hour later, an injection of the vehicle or a low dose of Δ⁹-THC that we have shown to exhibit slight efficacy in attenuating morphine abstinence signs was administered to each of the groups previously receiving the vehicle or CBD. Interactions between CBD and Δ⁹-THC were assessed during abstinence, precipitated one hour after the last series of injections. CBD had little effect on abstinence scores, but significantly increased the abstinence attenuating properties of Δ⁹-THC, Rotational behavior (turning), induced by Δ⁹-THC during abstinence, was also potentiated by CBD. These data extend previous reports of potentiation of pharmacological effects of THC by CBD to abstinence-attenuating properties and other effects of THC in morphine-dependent rats.     

Hypothermic action of delta 9-tetrahydrocannabinol, 11-hydroxy-delta 9-tetrahydrocannabinol and 11-hydroxy-delta 8-tetrahydrocannabinol in mice

The hypothermic activity of Δ⁹-tetrahydrocannabinol (Δ⁹-THC), a metabolite, 11-hydroxy-Δ⁹-tetrahydrocannabinol (11-OH-Δ⁹-THC) and 11-hydroxy-Δ⁸-tetrahydrocannabinol (11-OH-Δ⁸-THC) has been determined in male mice maintained at an ambient temperature of 20 ± 1°C. The mean body temperature of mice that received 2, 4, 16 or 32 mg/kg, i. v., of a tetrahydrocannabinol was significantly lower than that of vehicle treated mice (p <0.05) within 2 minutes after drug administration. Dose-response relationships show the intrinsic activity of Δ⁹-THC to be significantly greater than that of 11-OH-Δ⁹-THC or 11-OH-Δ⁸-THC in this system (p <0.05). The data indicate that the hypothermic activity of Δ⁹-THC cannot be explained entirely by metabolism to 11-OH-Δ⁹-THC.     

Effects of Δ8- and Δ9-Tetrahydrocannabinol on experimentally induced seizures

Effects of Δ⁸- and Δ⁹-tetrahydrocannabinol (Δ⁸- and Δ⁹-THC) on three experimentally induced seizure models, i.e., audiogenic seizure (AS) test, maximal electroshock seizure (MES) test and pentylenetetrazol (PTZ)-induced seizure test were determined in the audiogenic rat. Both tetrahydrocannabinols possess a dose-related anticonvulsant effect against AS, MES and PTZ-induced maximal seizure. Although anticonvulsant potencies do not significantly differ, Δ⁸THC is three times more neurotoxic than Δ⁹THC. In addition, both THC's are without effect on minimal seizure and lethality induced by PTZ. Furthermore, the low protective indexes (TD50/ED50) determined in this study suggest that Δ⁸ and Δ⁹ THC may have poor therapeutic potentials as antiepileptic drugs.     

Anticonvulsant properties of delta 9-tetrahydrocannabinol and other cannabinoids

Anticonvulsant doses of Δ⁹-tetrahydrocannabinol (Δ⁹-THC) markedly lower body temperature in mice at an ambient temperature of 22°C, but there is little such effect at 30°C. The anticonvulsant properties of Δ⁹-THC are as follows: The drug abolishes hind-limb extension in a maximal electroshock (MES) test, elevates both the MES (extensor) and 6-Hz-electroshock thresholds, exerts no effect on the 60-Hz-electroshock threshold, and enhances minimal seizures caused by pentylenetetrazol. All anticonvulsant properties studied, with the exception of the 60-Hz-electroshock threshold, were unaffected by the hypothermia resulting at 22°C. Additional experiments with Δ⁹-THC indicated that chronic treatment results in the development of tolerance, as determined by the MES test with rats. The four principal naturally occurring cannabinoids, Δ⁹-THC, Δ⁸-THC, cannabinol and cannabidiol, display anticonvulsant activity, as does the major, primary metabolite of Δ⁹-THC, 11-hydroxy-Δ⁹-THC. Of all agents investigated in mice, the synthetic cannabinoids, dimethylheptylpyran and its isomers, are the most potent anticonvulsants. The results of a study of the relative motor toxicity and anticonvulsant activity of the cannabinoids demonstrate that these properties are at least partially separable among the various agents.     

Behavioral comparisons of the stereoisomers of tetrahydrocannabinols

The potencies of (?)-$\text{trans}$-Δ⁹-THC, (+)-$\text{trans}$-Δ⁹-THC, (+)-$\text{cis}$-Δ⁹-THC, (?)-$\text{trans}$-Δ⁸-THC and (+)-$\text{trans}$-Δ⁸-THC were compared in several different species. (?)-$\text{trans}$-Δ⁹-THC was 100 times more potent than (+)-$\text{trans}$-Δ⁹-THC in depressing schedule-controlled responding in monkeys. The (+)-$\text{trans}$ isomers were less effective than their corresponding (?)-$\text{trans}$ isomers in the dog static-ataxia test, but potency ratios could not be determined due to a lack of dose-responsiveness of the (+)-$\text{trans}$ isomers. However, it appeared that their potency differed by at least ten fold. The potency of (+)-$\text{cis}$-Δ⁹-THC in the dog static-ataxia test was comparable to that of (+)-$\text{trans}$-Δ⁹-THC. The hypothermia in mice produced by the (?) isomers of $\text{trans}$-Δ⁹-THC and $\text{trans}$-Δ⁸-THC were 9.1 and 30.4 times greater than that produced by their respective (+)-isomers. Also, the potency ratio of the (+)- and (?)-$\text{trans}$-Δ⁹-THC was 5.6 as measured by depression of spontaneous activity in mice. The magnitude of the potency ratios of the THC stereo-isomers is dependent upon the species and the pharmacological test used.     

Effect of Delta-9-Tetrahydrocannabinol on Mouse Resistance to Systemic Candida albicans Infection

Delta-9-tetrahydrocannabinol (Δ⁹-THC), the psychoactive component of marijuana, is known to suppress the immune responses to bacterial, viral and protozoan infections, but its effects on fungal infections have not been studied. Therefore, we investigated the effects of chronic Δ⁹-THC treatment on mouse resistance to systemic Candida albicans (C. albicans) infection. To determine the outcome of chronic Δ⁹-THC treatment on primary, acute systemic candidiasis, c57BL/6 mice were given vehicle or Δ⁹-THC (16 mg/kg) in vehicle on days 1–4, 8–11 and 15–18. On day 19, mice were infected with 5×10⁵ C. albicans. We also determined the effect of chronic Δ⁹-THC (4–64 mg/kg) treatment on mice infected with a non-lethal dose of 7.5×10⁴ C. albicans on day 2, followed by a higher challenge with 5×10⁵ C. albicans on day 19. Mouse resistance to the infection was assessed by survival and tissue fungal load. Serum cytokine levels were determine to evaluate the immune responses. In the acute infection, chronic Δ⁹-THC treatment had no effect on mouse survival or tissue fungal load when compared to vehicle treated mice. However, Δ⁹-THC significantly suppressed IL-12p70 and IL-12p40 as well as marginally suppressed IL-17 versus vehicle treated mice. In comparison, when mice were given a secondary yeast infection, Δ⁹-THC significantly decreased survival, increased tissue fungal burden and suppressed serum IFN-γ and IL-12p40 levels compared to vehicle treated mice. The data showed that chronic Δ⁹-THC treatment decreased the efficacy of the memory immune response to candida infection, which correlated with a decrease in IFN-γ that was only observed after the secondary candida challenge.     

Relationship between the subcellular distribution of delta-9-tetrahydrocannabinol and its metabolites in rat brain and the duration of the effect on motor activity.

Female rats were injected intraperitoneally with 10 mg/kg of unlabelled delta-9-tetrahydrocannabinol (Δ⁹-THC) and their locomotor activity was recorded every 15 minutes for 12 hours. The maximum depressant effect was observed between the first and fourth hour and had completely disappeared by the eighth hour of treatment. In parallel experiments rats were injected with 10 mg/kg of ³H-delta-9-THC and decapitated either one, four or twelve hours later. The concentrations of unchanged delta-9-THC and metabolites in brain subcellular fractions were determined using thin layer chromatographic methods. There were no substantial differences in the relative specific activities of delta-9-THC or 11-OH-delta-9-THC between all fractions except cytosol, indicating no preferential site of accumulation. However, when the synaptosomal fraction was osmotically shocked, the concentration of delta-9-THC in nerve-ending membranes was markedly higher than that in vesicles or soluble fraction. Our results $\text{in vivo}$ showed a marked decline, over twelve hours, in the relative specific activities of delta-9-THC and 11-OH-delta-9-THC with a concomitant increase in the concentration of highly polar, non-extractable metabolites in all subfractions. It is suggested that the diminution of the depressant effect on motor activity may be related to the formation of highly polar, pharmacologically inactive metabolites of delta-9-THC and/or 11-OH-delta-9-THC inside the brain which do not easily migrate out of the cells.     

Endocrine effects of chronic intraventricular administration of delta9-tetrahydrocannabinol to prepuberal and adult male rats.

The daily intraventricular administration of Δ⁹-tetrahydrocannabinol (Δ⁹-THC) in microgram amounts for a week to prepuberal and adult rats had definite endocrine effects. Prostate weights were reduced and plasma and pituitary levels of growth hormone (GH) were increased in prepuberal rats. Pituitary levels of prolactin (PRL) were increased both in prepuberal and in adult animals while pituitary and adrenal weights and plasma corticosterone (B) levels were increased in adult rats. On the other hand, brain weights were significantly reduced by Δ⁹-THC in prepuberal and significantly increased in adult animals. No changes in brain levels of noradrenaline (NA), dopamine (DA) or serotonin (5-HT) were found in treated animals. These results indicate that Δ⁹-THC may modify some endocrine functions when injected directly into the brain in microgram amounts. They show on the other hand that young and adult animals may respond differently to the chronic administration of the psychoactive drug, although the difference may be due to a biphasic effect of different doses.     

Acquisition of tolerance to Δ-9-THC as measured by the response of a cellular function

The development of tolerance to delta-9-tetrahydrocannabinol (Δ-9-THC) was investigated by measuring respiration in brain tissue after acute or chronic administration. Mice were given either single or seven daily repeated intraperitoneal injections of 50 mg/Kg of delta-9-tetrahydrocannabinol (Δ-9-THC) or control vehicle. The final injection for all drug treated animals included radiolabeled ³H-Δ-9-THC. The mice were sacrificed at 1 hour, 2 hours, 4 hours, 24 hours, and 7 days after the final injection. Δ-9-THC depressed respiration, but after repeated injections was significantly less effective in this regard, indicating acquisition of tolerance to Δ-9-THC. Because the concentration of radiolabeled cannabinoids in brain tissue from each group is not appreciably different, a cellular as opposed to distributional mode of tolerance is suggested.     

Δ-Tetrahydrocannabinol regulates the p53 post-translational modifiers Murine double minute 2 and the Small Ubiquitin MOdifier protein in the rat brain

The phytocannabinoid Δ⁹-Tetrahydrocannabinol (Δ⁹-THC), the main psychoactive cannabinoid in cannabis, activates a number of signalling cascades including p53. This study examines the role of Δ⁹-THC in regulating the p53 post-translational modifier proteins, Murine double minute (Mdm2) and Small Ubquitin-like MOdifier protein 1 (SUMO-1) in cortical neurons. Δ⁹-THC increased both Mdm2 and SUMO-1 protein expression and induced the deSUMOylation of p53 in a cannabinoid receptor type 1 (CB₁)-receptor dependent manner. We demonstrate that Δ⁹-THC decreased the SUMOylation of the CB₁ receptor. The data reveal a novel role for cannabinoid receptor activation in modulating the SUMO regulatory system.

Structured summary

MINT-7266621: Cb1 (uniprotkb:P20272) physically interacts (MI:0915) with SUMO-1 (uniprotkb:Q5I0H3) by anti bait coimmunoprecipitation(MI:0006)MINT-7266633: SUMO-1 (uniprotkb:Q5I0H3) and Cb1 (uniprotkb:P20272) colocalize (MI:0403) by fluorescence microscopy (MI:0416)MINT-7266611: p53 (uniprotkb:P10361) physically interacts (MI:0915) with SUMO-1 (uniprotkb:Q5I0H3) by anti bait coimmunoprecipitation (MI:0006)     

Δ9-tetrahydrocannabinol and dimethylheptylpyran induced tachycardia in the conscious rat

Since cannabinoids lead to dose-related tachycardia in man but dose dependent bradycardia has been reported thus far in laboratory animals, there would seem to be a need for an experimental model in which the effect seen in man (tachycardia) could be reproduced and explored. In the conscious rat, the compounds Δ⁹-tetrahydrocannabinol (Δ⁹-THC) and dimethylheptylpyran (DMHP) injected i.p. led to dose-related increases in heart rate at 10–20 minutes after administration. In vehicle (ethanol) control rats there were small increases in heart rate. Propranolol given before Δ⁹-THC resulted in a parallel shift to the right of the dose-effect curve. Adrenalectomy led to a significant (p<0.01) decrease in tachycardia following Δ⁹-THC and DMHP while ganglionic block markedly decreased the heart rate increases after Δ⁹-THC (p<0.001). Systolic blood pressure at nearly all doses of Δ⁹-THC was minimally affected, although it tended to decrease with increasing dose. Tachycardia in the rat may be the result of a centrally mediated release of epinephrine from the adrenal gland.     

A Structural Insight into the Molecular Recognition of a (−)-Δ-Tetrahydrocannabinol and the Development of a Sensitive, One-Step, Homogeneous Immunocomplex-Based Assay for Its Detection

(−)-Δ⁹-Tetrahydrocannabinol (THC) is the main psychoactive compound found in cannabis. In this study, an anti-THC Fab fragment, designed T3, was isolated from a display library cloned from the spleen cells of a mouse immunized with a THC-bovine serum albumin conjugate, and the crystal structures of the T3 Fab in its free form and in complex with THC were determined at 1.9 Å and 2.0 Å resolution, respectively. The THC binding site of the T3 Fab is a narrow cavity: the n-pentyl group of THC protrudes deep into the interface area between the variable domains and the C₁₀ monoterpene moiety of the hapten is partially exposed to solvent. The metabolites of THC, with modifications in the C₁₀ monoterpene moiety, 11-nor-9-carboxy-Δ⁹-tetrahydrocannabinol and 11-hydroxy-Δ⁹-tetrahydrocannabinol, are bound by the T3 Fab with a higher affinity than THC. The crystal structures suggest that Ser52H and Arg53H of the T3 Fab are able to make hydrogen bonds with the metabolites, which leads to an increased binding against these metabolites. By developing a T3 Fab-Δ⁹-THC immunocomplex binding antibody from a naïve antibody phage display library, the specificity of the Δ⁹-THC binding is highly increased, which allows a one-step, homogeneous, fluorescence resonance energy transfer-based sensitive immunoassay, with a detection limit of 20 ng/ml from saliva samples.     

Separate radioimmune measurements of body fluid Δ9-THC and 11-nor-9-carboxy-Δ9-THC

Simultaneous native molecule and discrete metabolite immune assays were performed after exposure of subjects to standardized Δ⁹-THC cigarettes. Plasma (and urine) 11-nor-9-carboxy-Δ⁹-THC remains elevated long after Δ⁹-THC becomes scant or undetectable enabling simple radioimmune determination of recent versus distant exposure to multiple cigarettes.     

Antineuropathic Profile of N-Palmitoylethanolamine in a Rat Model of Oxaliplatin-Induced Neurotoxicity

Neurotoxicity is a main side effect of the anticancer drug oxaliplatin. The development of a neuropathic syndrome impairs quality of life and potentially results in chemotherapy dose reductions and/or early discontinuation. In the complex pattern of molecular and morphological alterations induced by oxaliplatin in the nervous system, an important activation of glia has been preclinically evidenced. N-Palmitoylethanolamine (PEA) modulates glial cells and exerts antinociceptive effects in several animal models. In order to improve the therapeutic chances for chemotherapy-dependent neuropathy management, the role of PEA was investigated in a rat model of oxaliplatin-induced neuropathy (2.4 mg kg^-1 daily, intraperitoneally). On day 21, a single administration of PEA (30 mg kg^-1 i.p.) was able to reduce oxaliplatin-dependent pain induced by mechanical and thermal stimuli. The repeated treatment with PEA (30 mg kg^-1 daily i.p. for 21 days, from the first oxaliplatin injection) prevented lowering of pain threshold as well as increased pain on suprathreshold stimulation. Ex vivo histological and molecular analysis of dorsal root ganglia, peripheral nerves and spinal cord highlighted neuroprotective effects and glia-activation prevention induced by PEA repeated administration. The protective effect of PEA resulted in the normalization of the electrophysiological activity of the spinal nociceptive neurons. Finally, PEA did not alter the oxaliplatin-induced mortality of the human colon cancer cell line HT-29. The efficacy of PEA in neuropathic pain control and in preventing nervous tissue alteration candidates this endogenous compound as disease modifying agent. These characteristics, joined to the safety profile, suggest the usefulness of PEA in chemotherapy-induced neuropathy.     

Effects of Δ9-tetrahydrocannabinol on neurotransmitter accumulation and release mechanisms in rat forebrain synaptosomes

The effects of (?)?Δ⁹-THC were studied on the release and accumulation of ³H5HT and ³HNE in a rat forebrain synaptosomal preparation. These studies were designed to evaluate the possible sites of action of Δ⁹-THC on these two processes. Δ⁹-THC inhibited the accumulation of ³H-leucine, ³HNE, and ³H5HT, as well as facilitated the release of the latter two amines (to a lesser degree), but had no effect on the release of ³H-leucine. Eighteen-hour pre-treatment with reserpine diminished the ability of Δ⁹-THC to induce release of ³H5HT, but had no effect on the $\text{in vitro}$ inhibition of synaptosomal uptake of this amine. Concentrations of Δ⁹-THC which blocked the uptake of ³H5HT also reduced the conversion of ³H5HT to ³H-5-hydroxy-3-indoleacetic acid. However, Δ⁹-THC, at concentrations which facilitated release of ³H5HT from preloaded synaptosomes, increased the amount of ³H5HIAA found in the medium. Taken together, these data suggest that Δ⁹-THC facilitates release from the synaptic vesicle and retards accumulation at the neuronal membrane.     

Inhibition of sea urchin fertilization by fatty acid ethanolamides and cannabinoids

The influence of saturated and unsaturated fatty acid ethanolamides as well as Δ⁹-tetrahydrocannabinol (Δ⁹-THC), WIN 55,212-2 and cannabinoid CB₁ receptor antagonist SR 141716 on sea urchin fertilization was studied. The ethanolamides of arachidonic, oleic and linoleic acids but not saturated fatty acid (C₁₄–C₂₀) derivatives inhibited fertilization when pre-incubated with sperm cells. Δ⁹-THC and WIN 55,212-2 also inhibited fertilization, Δ⁹-THC being ten times as potent as WIN 55,212-2. Selective cannabinoid CB₁ receptor antagonist SR 141716 also blocked fertilization and did not antagonize the action of Δ⁹-THC. The obtained results indicate that different unsaturated fatty acid ethanolamides may control sea urchin fertilization, and that sea urchin sperm cell cannabinoid receptor may differ from the known cannabinoid receptor subtypes.     

Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ-THC: Mechanism underlying greater toxicity?

K2 or Spice products are emerging drugs of abuse that contain synthetic cannabinoids (SCBs). Although assumed by many teens and first time drug users to be a “safe” and “legal” alternative to marijuana, many recent reports indicate that SCBs present in K2 produce toxicity not associated with the primary psychoactive component of marijuana, ?⁹-tetrahydrocannabinol (Δ⁹-THC). This mini-review will summarize recent evidence that use of K2 products poses greater health risks relative to marijuana, and suggest that distinct pharmacological properties and metabolism of SCBs relative to Δ⁹-THC may contribute to the observed toxicity. Studies reviewed will indicate that in contrast to partial agonist properties of Δ⁹-THC typically observed in vitro, SCBs in K2 products act as full cannabinoid receptor type 1 (CB1R) and type 2 (CB2R) agonists in both cellular assays and animal studies. Furthermore, unlike Δ⁹-THC metabolism, several SCB metabolites retain high affinity for, and exhibit a range of intrinsic activities at, CB1 and CB2Rs. Finally, several reports indicate that although quasi-legal SCBs initially evaded detection and legal consequences, these presumed “advantages” have been limited by new legislation and development of product and human testing capabilities. Collectively, evidence reported in this mini-review suggests that K2 products are neither safe nor legal alternatives to marijuana. Instead, enhanced toxicity of K2 products relative to marijuana, perhaps resulting from the combined actions of a complex mixture of different SCBs present and their active metabolites that retain high affinity for CB1 and CB2Rs, highlights the inherent danger that may accompany use of these substances.     

The effects of Δ9-tetrahydrocannabinol Δ9-THC) on the regional concentrations of spermidine in the rat brain

The effects of intravenous administration of Δ⁹-tetrahydrocannabinol (Δ⁹-THC, 2 mg/kg, i.v.) on the regional brain spermidine concentrations of the rat were examined. Thirty minutes after vehicle treatment, the spermidine concentrations were: for the medulla oblongata/pons, 68.2 ± 7.7 μg/g; the hypothalamus, 67.7 ± 2.6 μg/g; the midbrain, 59.1 ± 4.4 μg/g; the cerebellum, 47.3 ± 5.9 μg/g and for the cortex, 13.8 ± 0.8 μg/g. Thirty minutes after Δ⁹-THC, these concentrations were reduced in the midbrain (47.0 ± 8.0% of control, P < 0.0001) and cortex (69.4 ± 7.4% of control, P < 0.009). The spermidine concentrations were not significantly altered in the medulla oblongata/pons (86.5 ± 13.3%, P > 0.36), hypothalamus (107.2 ± 11.8, P > 0.36) or cerebellum (89.0 ± 14.4%, P < 0.48). These results suggest that spermidine within the midbrain and cortex may be involved in the expression of some of the actions of Δ⁹-THC.